✦ LIBER ✦

Anti-tumour necrosis factor-α therapy for severe enteropathy in patients with common variable immunodeficiency (CVID)

✍ Scribed by I. Chua; R. Standish; S. Lear; M. Harbord; E. Eren; M. Raeiszadeh; S. Workman; D. Webster

Book ID: 108699690
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 263 KB
Volume: 150
Category: Article
ISSN: 0009-9104
DOI: 10.1111/j.1365-2249.2007.03481.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

QuantiFERON®-TB Gold testing for tubercu

QuantiFERON®-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor α therapy

✍ N. Desai; Y. Raste; N.T. Cooke; C.C. Harland 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Tuberculosis and tumour necrosis factor-

Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians

✍ A. Perlmutter; A. Mittal; A. Menter 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Comparison of tuberculin skin test and i

Comparison of tuberculin skin test and interferon-γ assays in patients with moderate to severe psoriasis who are candidates for antitumour necrosis factor-α therapy

✍ N. Balato; F. Ayala; F. Gaudiello; G. Monfrecola; G. Cimmino; A. Ponticiello; M. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Reduction in the incidence of myocardial

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

✍ W. G. Dixon; K. D. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Single-center series and systematic revi

Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?

✍ Nannini, Carlotta ;Cantini, Fabrizio ;Niccoli, Laura ;CassarÀ, Emanuele ;Salvara 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views